Bevacizumab is a humanized monoclonal antibody targeting the most important factor implicated in tumor angiogenesis called vascular endothelial growth factor (VEGF), and was the first molecule developed in the treatment of metastatic CRC. This evidence concerns the gene VEGFA and neoplasm.